The field of gene editing is expanding rapidly. A team of scientists in China recently injected CRISPR-edited cells into a human patient for the first time — potentially setting off a biomedical race between China and the United States, as reported in the international scientific journal Nature.
More significant developments are expected in the years to come. The global CRISPR market is forecast to grow at an astonishing compound annual growth rate (CAGR) of 35% from 2016 to 2022, according to Inkwood Research, a market intelligence firm. The number of scientific papers published on CRISPR continues to soar, from below 200 papers in 2012 to more than 1,200 papers in 2015.











